Aspheric IOLs no. 1 choice for glaucoma patients

Article

An aspheric IOL may be considered the implant design of choice for most patients with glaucoma who require cataract surgery, said Richard L. Lindstrom, MD.

An aspheric IOL may be considered the implant design of choice for most patients with glaucoma who require cataract surgery, said Richard L. Lindstrom, MD.

"Providing the best quality vision is paramount in the visually compromised glaucoma patient," said Dr Lindstrom, founder and attending surgeon, Minnesota Eye Consultants, Minneapolis, US. "These individuals are known to have reduced contrast sensitivity that is related to a reduction in retinal ganglion cells.

"Given this neuronal influence, it is rational to do whatever we can to maximize contrast sensitivity on the basis of optics, and that is accomplished best with the use of an aspheric IOL," he added.

Dr Lindstrom noted there is good evidence that aspheric IOLs enhance contrast sensitivity by reducing total spherical aberration in the eye. The only situation where a spherical IOL would be preferred over an aspheric implant would be in the rare instance of a patient with glaucoma who has negative corneal spherical aberration related to previous LASIK for hyperopia.

In general, presbyopia-correcting IOLs - and particularly, current-generation multifocal designs - should be avoided in patients with glaucoma because of a potential to compromise contrast sensitivity. Laboratory measurements of modulation transfer function, however, show that an investigational, next-generation design of a proprietary accommodating IOL (crystalens HD-100; eyeonics/Bausch & Lomb) outperformed a previous model of the accommodating IOL, as well as multifocal presbyopia-correcting implants.

"For now, multifocality might be considered only if visual loss [from glaucoma] is mild and expected to stay that way," Dr Lindstrom said. "When available, the new accommodating IOL may become a reasonable compromise for select glaucoma patients who want to reduce their dependence upon glasses."

 

Read

ASCRS 2008 meeting highlights.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.